Full-Life Technologies Co., Ltd. announced two key appointments to its Radioisotope Technology leadership team and the establishment of a Radioisotope Technology Advisory Board that deepen the company’s expertise in radioisotope technology. Joining the company’s management team are Full-Life co-founder and board member Hong-hoi Ting, D.Phil. as Chief Strategy Officer, and James McCarter, Ph.D. as Vice President, Head of Radioisotope Technology Research.
Also Read: PlantX Celebrates Grand Opening of XMarket Uptown in Chicago
The company’s newly formed Radioisotope Technology Advisory Board is composed of well-known industry leaders in the field of radioisotope technology. The founding advisory board members include: William Diamond, Ph.D., former Senior Scientist at Atomic Energy Canada; Carl Ross, Ph.D., former physicist at the National Research Council of Canada; and Herbert Moore, Ph.D., former research leader at New England DuPont.
“The appointments of Dr. Ting and Dr. McCarter provide Full-Life with great depth and breadth of business and technical expertise in radioisotopes and radiopharmaceutical technology as we advance and expand our robust pipeline,” said Philippe van Put, General Manager of Full-Life Europe. “Dr. Ting, who has helped set Full-Life’s direction as a co-founder and board member, has an outstanding track record in building and guiding the growth of radio therapeutics and health care companies. Dr. McCarter brings more than 18 years of experience as a leader in engineering physics, particle accelerators, and radioisotope technology.”
Mr. Van Put continued, “The distinguished experts on our Radioisotope Technology Advisory Board have a wealth of experience that spans radioisotope technology discovery, development, and production and reflects our ambition to build a fully integrated platform for developing next-generation targeted radio therapeutics. Their expertise and insights will help us fulfill the company’s mission.”
Dr. Ting is a scientist, entrepreneur, and angel investor. Before joining Full-Life, he was the first China General Manager of Amersham International Plc. During his tenure at Amersham, he started a very successful joint venture with China Isotope Corporation, CICAM, one of the world’s largest smoke detector alpha-foil manufacturers. He played a role in the launch of Amersham Kexing Pharmaceutical (Shanghai), a joint venture with C.A.S. Shanghai Institute of Nuclear Research, for the cyclotron production of medical radioisotopes. In addition, he served as CEO and co-founder of Nanomab Technology, Oxford Vacmedix, and Biovue Technology Ltd. and was a co-founder of Genemedix Plc., a biotechnology company that was co-listed on the main boards of London Stock Exchange (LSE) and Shanghai Stock Exchange (SSE) before its acquisition by the Reliance Group. He has also served in consulting capacities with Westinghouse Electric, Johnson & Johnson, GE Healthcare, CGN Nuclear Technology, and ITM GmbH. Dr. Ting received his D.Phil. from Oxford University and held a permanent university senior research staff position under Professor J.E. Baldwin’s group before pursuing a career in the industry.